Literature DB >> 11101071

Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda.

M C Boily1, C M Lowndes, M Alary.   

Abstract

OBJECTIVES: To study the dynamics of a mass treatment programme for sexually transmitted diseases (STD) on prevalence of STD and HIV incidence in order to help explain the results of the STD mass treatment community trial in Rakai, Uganda.
METHODS: The analysis is based on simulations of STD mass treatment interventions using a deterministic model describing the course of STD and HIV transmission over time and incorporating demographic, biological and behavioural parameters. The mass intervention modelled mimics that used in the Rakai community trial.
RESULTS: Mass treatment decreases STD prevalence to a very low level compared with baseline but is unsuccessful at eradicating the infection. STD prevalences return to baseline fairly rapidly after each round of mass treatment. Under different realistic scenarios, the fraction of HIV cases prevented by STD mass treatment assuming uniform 80% coverage of high- and low-risk groups, over the 20-month period following the first round of treatment, was greater than 35%. If, however, differential coverage is assumed, for example that while the total coverage is still 80%, only 40 or 25% of those at high risk are treated, the HIV preventable fraction is reduced, to 19 and 15% respectively (undetectable given the statistical power of the study). The tremendous impact of differential coverage can also be observed even in the early stage of the HIV epidemic.
CONCLUSIONS: In the Rakai trial, mass treatment may have had an effect, although transient, on all STD prevalences, which could have had positive repercussions for HIV incidence. This modelling exercise suggests that although an 80% coverage appears high, the differential coverage of low- and high-risk populations may seriously impair our ability to test the STD-HIV interaction hypothesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101071     DOI: 10.1097/00002030-200011100-00022

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Efforts to Control Sexually Transmitted Infections As a Means to Limit HIV Transmission: What Is the Evidence?

Authors:  Gina Dallabetta; Graham Neilsen
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 2.  Efforts to control sexually transmitted infections as a means to limit HIV transmission: what is the evidence?

Authors:  Gina Dallabetta; Graham Neilson
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.071

3.  The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.

Authors:  Eric Ross; Frank Tanser; Pamela Pei; Marie-Louise Newell; Elena Losina; Rodolphe Thiebaut; Milton Weinstein; Kenneth Freedberg; Xavier Anglaret; Callie Scott; Francois Dabis; Rochelle Walensky
Journal:  HIV Clin Trials       Date:  2014 Sep-Oct

4.  Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences.

Authors:  Alethea W McCormick; Nadia N Abuelezam; Thomas Fussell; George R Seage; Marc Lipsitch
Journal:  Epidemics       Date:  2017-04-02       Impact factor: 4.396

5.  Evaluating large-scale HIV prevention interventions: study design for an integrated mathematical modelling approach.

Authors:  M-C Boily; C M Lowndes; P Vickerman; L Kumaranayake; J Blanchard; S Moses; B M Ramesh; M Pickles; C Watts; R Washington; S Reza-Paul; A C Labbe; R M Anderson; K N Deering; M Alary
Journal:  Sex Transm Infect       Date:  2007-10-17       Impact factor: 3.519

Review 6.  HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.

Authors:  Wim Delva; Jeffrey W Eaton; Fei Meng; Christophe Fraser; Richard G White; Peter Vickerman; Marie-Claude Boily; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

Review 7.  HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention.

Authors:  Marie-Claude Boily; Benoît Mâsse; Ramzi Alsallaq; Nancy S Padian; Jeffrey W Eaton; Juan F Vesga; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

8.  Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India.

Authors:  Marie-Claude Boily; Michael Pickles; Catherine M Lowndes; Banadakoppa M Ramesh; Reynold Washington; Stephen Moses; Kathleen N Deering; Kate M Mitchell; Sushena Reza-Paul; James Blanchard; Anna Vassall; Michel Alary; Peter Vickerman
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

9.  Modelling the impact of antiretroviral use in resource-poor settings.

Authors:  Rebecca F Baggaley; Geoff P Garnett; Neil M Ferguson
Journal:  PLoS Med       Date:  2006-03-14       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.